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Abstract: 
Treatments for allergic disease block the effects of mediators released from activated mast cells 
and blood basophils. A panel of fullerene derivatives was synthesized and tested for their ability 
to preempt the release of allergic mediators in vitro and in vivo. The fullerene C70 -tetraglycolic 
acid significantly inhibited degranulation and cytokine production from mast cells and basophils, 
while C70 –tetrainositol blocked only cytokine production in mast cells and degranulation and 
cytokine production in basophils. The early phase of FcεRI inhibition was dependent on the 
blunted release of intracellular calcium stores, elevations in reactive oxygen species, and several 
signaling molecules. Gene microarray studies further showed the two fullerene derivatives 
inhibited late phase responses in very different ways. C70 -tetraglycolic acid was able to block 
mast cell-driven anaphylaxis in vivo, while C70 -tetrainositol did not. No toxicity was observed 
with either compound. These findings demonstrate the biological effects of fullerenes critically 
depends on the moieties added to the carbon cage and suggest they act on different FcεRI-
specific molecules in mast cells and basophils. These next generation fullerene derivatives 
represent a new class of compounds that interfere with FcεRI signaling pathways to stabilize 
mast cells and basophils. Thus, fullerene based therapies may be a new approach for treating 
allergic diseases. 
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Article:  
Mast cells (MC) are granule-rich tissue cells that significantly contribute to a wide range of 
diseases through the release of noxious mediators. Peripheral blood basophils (PBB) are similar 
to MC in that they are the only leukocytes that contain prestored histamine within their granules. 
The high-affinity IgE receptor, FcεRI, is one of many ways in which MC/PBB can be activated 
for mediator release. Cross-linking Immunoglobulin E (IgE)- primed FcεRI leads to the release 
of various preformed and newly generated mediators that can cause allergic disease.1 Moreover, 
MC are suspected to play a role in other inflammatory disorders such as arthritis and 
cardiovascular disease through non-FcεRI mediated mechanisms.2,3 ) Basophils, also established 
effector cells in allergic disease, have recently been implicated as playing a major role in 
adaptive and innate immunity. 4,5 Thus, finding new ways of preventing MC/PBB activation and 
subsequent mediator release is of clinical importance. 
Nanotechnology encompasses a multidisciplinary scientific field that is rapidly increasing and 
has the potential to play an important role in many branches of science.6 One type of 
nanomaterial is buckminsterfullerene (fullerene), which are carbon spheres. 7 Fullerenes have a 
unique cage structure with delocalized π molecular orbital electrons. This structure confers 
unusual activity in electron transfer systems due to their low reorganization energy, low-lying 
excited states (singlet and triplet), and extended triplet lifetimes. Further, the spherical 
configuration of the planar benzene rings imposes an unusual constraint on these π electron 
orbitals. As the core carbon cage is insoluble in aqueous solutions, fullerene derivatives (FD) 
have been developed with a wide variety of side chain moieties that make them more compatible 
with biological systems.  
These unique properties of FD have led to their potential as a new way for treating a wide range 
of diseases and pathologies.8 These include multiple sclerosis, 9 neurodegenerative disease,10 
HIV infection,11 cancer,12 radiation exposure,13 ischemia, 14 and general inflammation.15,16 
Moreover, mice chronically treated with FD have significantly extended lifespans compared to 
littermate controls.17 While it is clear that these molecules possess traits that may potentially be 
beneficial for therapies, they have yet to be tested in humans given the lack of a clearly 
efficacious and characterized candidate for a specific disease. Safety is a concern as it is for any 
new class of compounds. 18 Studies investigating one class of structurally related FD cannot be 
extrapolated to represent all FD; each new molecular entity must be investigated separately. 
Proof-of-principle studies to identify a specific candidate need to be established before relevant 
toxicity and pharmacokinetic studies of that candidate can be performed. We showed previously 
that water-soluble FD could blunt MC and PBB responses.19 However, the FD used previously 
were mixtures of many different isomers limiting their therapeutic potential and made dissecting 
their mechanism of action difficult. The goal of this study was to develop and test next 
generation FD (highly purified and characterized) to establish proof-of-principle as candidates 
for diseases strongly influenced by MC and PBB activation through FcεRI. 
To achieve this goal, a panel of water-soluble FD was synthesized and tested in different 
concentrations for their ability to inhibit FcεRI-mediated MC/PBB activation. It is shown for the 
first time that the biological function of FD on MC/PBB critically depends on the class of 
moieties added to the carbon cage; some constructs had no effect, others were effective at 
blocking degranulation and cytokine release, and another group blocked cytokine production 
only. Two representative FD, C70 tetragycolate (TGA) and C70 tetrainositol (Inos) were further 
examined for differences in their mechanisms of action. We examined early activation events 
(reactive oxygen species [ROS], Ca 2+ , and phosphorylation of signaling molecules) and later 
events (gene expression by microarray and quantification of those FcεRI-activated signaling 
molecules most affected by FD pretreatment). For select FD (TGA), it is further shown that this 
behavior translates to in vivo inhibition of MC-dependent anaphylaxis. These results show that 
appropriate FD may be effective treatments for diseases that are influenced by MC activation. 
More importantly, we demonstrate for the first time that FD can be engineered at the nano-scale 
level to control specific signal transduction pathways affecting cell function. 
Methods 
Fullerene derivatives 
All FD were synthesized at Luna Innovations Incorporated. A representative synthesis protocol 
is given in Supplementary Figure S1. Each derivative was characterized using matrix assisted 
laser desorption ionization mass spectrometry, nuclear magnetic resonance, high-performance 
liquid chromatography, and dynamic light scatter. All FD were tested for cell toxicity by 
incubation with increasing concentrations up to 100 μg/mL and viability counts taken on days 
3, 6, and 9. No toxicity was observed with any of the FD compared to control cells (not shown). 
MC/PBB FD culture and FcεRI-mediated activation 
Human skin tissue was received from the Cooperative Human Tissue Network and MC purified 
and cultured as described. 20 The MC were cultured in media containing stem cell factor that is 
removed from the culture 24 hours prior to experimentation. PBB were obtained from two 
sources: donors recruited under an Internal Review Board (IRB)-approved protocol after 
informed consent or from leukopheresis packs obtained from the Johns Hopkins Hemapheresis 
Center . PBB were purified to ≥99% purity as previously described. 21–23 Purifi ed PBB were 
incubated overnight (20 hours) with FD (5 μg/mL) or vehicle control and a minimal 
(nonstimulatory) concentration of IL-3 (2 pg/mL) to prevent apoptosis.22 Th e next day, cells 
were washed and aliquoted for the histamine release assay by treatment with 0.1 mg/mL of goat 
polyclonal anti-IgE, buff er alone (spontaneous release) or perchloric acid (total histamine 
determination). Histamine was quantifi ed in cell free supernatants using automated fl uorimetry 
in duplicate. In a second set of experiments, the two FD (at 5 μg/mL) were incubated with PBB 
for 20 hours, washed cells were stimulated with 15 ng/mL anti-IgE for 18 hours in duplicate, and 
supernatants were collected for quantification of IL-13 by in-house enzymelinked 
immunosorbent assay (ELISA) . The doses of anti-IgE are optimal for activation of PBB based 
on previous studies. 
For activation, MC were suspended in fresh medium (without cytokines) and incubated for 16 
hours with or without FD at 37°C in a 6% CO 2 incubator. The 16-hour time point was chosen 
based on preliminary experiments demonstrating this was optimal for inhibition of mediator 
release (not shown) and uptake within FcεRI cells.24 The next morning, cells were washed and 
stimulated with anti-FcεRI antibodies (Abs) (3B4; 1 μg/mL) for 30 minutes (β-
hexosaminidase) or overnight (granulocyte macrophage colonystimulating factor [GMC-SF]) at 
37°C in a 6% CO 2 incubator and mediator release measured as described previously.25 All MC 
mediator release studies were performed in triplicate. 
Western blotting and phospho-signaling quantification 
Cell lysate preparation and Western blotting were performed using a protocol optimized for 
extracting phosphoproteins from human MC. 26 Following activation, cells were lysed directly in 
boiling denaturing sample buffer consisting of tris-buffered saline with triton-X-100 (0.5%) and 
protease and phosphatase inhibitors. The cell suspension was then passed through a 20-gauge 
needle, boiled, and centrifuged to remove cell debris. Proteins were separated on 8% or 10% 
NuPage Tris-Bis gels using Licor running buffer. Western blotting was performed using Licor 
blocking buffer and IR800 and IR700 antirabbit F(ab) 2 secondary Abs (1:1,000). Primary Abs 
were from Cell Signaling Technologies (Danvers, MA, USA) or Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) unless otherwise noted. Band intensities were captured using the 
Odyssey Imaging System (Li-Cor Biosciences, Lincoln, NE, USA) and bands quantified by 
measuring the number of pixels in each band using a box drawn for the same area of 
measurement for each separate blot. The band intensity was then normalized for loading by 
dividing the number of pixels in each band with the housekeeping band intensity (β-actin) 
performed on the same blot. 
Calcium and ROS measurement 
MC were pretreated with or without FD as above, washed with Tyrodes buffer supplemented 
with bovine serum albumin (BSA), and incubated with Fura-2 AM (2 μm) for 30 minutes at 
37°C . Cells were washed, stimulated with anti-FcεRI, and calcium flux measured in real time on 
a Perkin Elmer LS55 Spectrofluorometer. For ROS production, cells were exposed to FD as 
above. After washing, cells were resuspended in X-Vivo medium containing 5 μm 
dichlorodihydrofl uorescein (DCF) at 37°C for 30 minutes, washed, and activation-induced 
changes in mean fluorescence were measured with excitation at 502 nm and emission at 523 nm 
for 15 minutes. 19 The data are presented as fluorescence intensity of the 523 nm emission over 
time. All experiments were performed in triplicate and degranulation was measured in parallel. 
Separate experiments were performed to ensure that the FD do not interfere with indicator dye 
binding (not shown). 
Gene microarray studies and validation using Western blotting or flow cytometry 
MC (1 × 10 7 cell/condition; each condition performed in triplicate) were incubated with or 
without FD as above and incubated with or without anti-FcεRI antibodies for 10 minutes, 
supernatants were removed (to remove preformed mediators), and fresh warm medium 
containing anti-FcεRI antibodies (1 μg/mL) added for 
2 hours. Cells were centrifuged, the supernatant and the pellet immediately frozen, and 
microarray performed using the Human Whole Genome OneArrayTM gene expression profi ling 
service (Phalanx Biotech Group , Palo Alto, CA, USA) . Separate samples, assayed in parallel, 
were lysed and protein expression was analyzed by Western blotting or flow cytometry (CD45) 
as described.27 
For microarray, RNA was isolated using the Ambion MessageAmp aRNA kit (Applied 
Biosystems/Ambion, Austin, TX, USA); all samples passed the internal quality control checks. 
For hybridization, each sample was run in triplicate. Optical density was measured by NanoDrop 
ND-1000. The ratio of absorbance at 260 nm and 280 nm provides an estimate of RNA purity. 
Samples were found to have ratios between 1.8 and 2.2 indicating highly pure samples. The 
reactive amino group of 5-(3-aminoallyl)-UTP/5-(3-aminoallyl)-dUTP was used to conjugate the 
purified aRNA/cDNA with the NHSCyDye. Labeling efficiency was calculated by the 
concentration of CyDye and aRNA/cDNA that was above 10. For hybridization, 10 μg Cy5-
labeled aRNA was utilized by the Phalanx Hybridization Protocol Array Version HOA 4.3. 
Pearson correlation tables ( R values) for each technical repeat were calculated from raw log2 
intensity ( R ) and normalized log2 intensity ( N ) values and compared to each other. Only 
probes with p value (detected) less than 0.05 were included in the calculation. This analysis 
showed good correlation between platforms when filtered stringently for fold change and loosely 
for significance ( p value). Greater than 95% of the samples had R values of 0.8 or greater 
indicating strong correlation between the two parameters. 
In order to examine the genes most affected by FD preincubation, the resulting values were 
sorted and filtered the following way. First, the mean (±standard deviation [SD]) of the six 
values from each condition for each of the 30,970 genes was calculated. Second, only 
normalized value intensities of >100 were included so that follow-up detection of protein levels 
would be more likely to be successful. Third, these data were further truncated to include only 
normalized data in which the average FcεRI activation (without pretreatment) significantly ( p < 
0.05) increased at least 10% compared to non-FcεRI resting cells. Fourth, the genes with >10% 
upregulation by FcεRI stimulation alone were compared to those samples pretreated with each 
FD and only those showing at least >20% inhibition or >20% upregulation (nontreated + 
anti-FcεRI compared to treated + anti-FcεRI) were examined. Data are presented as the average 
percentage downregulated with FD treatment derived from the following equation. 
 
Downregulation observed at the gene level was verified at the protein level for several 
representative molecules using Western blotting or flow cytometry. A complete list of those 
genes downregulated or upregulated by each FD (>20%) is shown in Supplemental File S1. 
Mouse models of anaphylaxis and assessment of toxicity 
All studies were approved by the Virginia Commonwealth University IACUC. MC-dependent 
anaphylaxis and treatments are described. 19 Briefl y, female C57BL/6J mice (Jackson 
Laboratory, Bar Harbor, ME, USA) aged 10–12 weeks were injected i.p. with 50 μg IgE-
dinitrophenol (DNP) . Two hours later mice were injected i.p. with TGA, Inos (100 ng/200 μL 
in phosphate buffered saline [PBS]), or 200 μL PBS alone as a vehicle control . After 16 hours, 
mice were challenged i.p. with 100 μg DNP-BSA (Sigma-Aldrich, St. Louis, MO, USA) in 100 
μL PBS. Body temperature measurements were recorded with a digital rectal thermometer 
every 10 minutes for a total of 50 minutes. Peripheral blood was harvested by cardiac puncture 
50 minutes after antigen challenge and serum histamine measurements determined by ELISA. 
To examine potential toxicity, alanine aminotranferease (ALT) and aspartate aminotransferase 
(AST) were measured in serum. These enzymes leak out into the general circulation when the 
liver is injured.28 Mice were treated with or without 1,000 μg/100 μL (50 times more than used 
for the in vivo study) of TGA or Inos by tail vein injection and i.p. After 2 and 14 days, mice 
were sacrificed and blood obtained by cardiac puncture. ALT and AST activity were measured 
as described. 28 Data are presented as an average of four (untreated) or four (treated) mice ± SD. 
Results 
FD diff erentially affect FcεRI-mediated degranulation 
A panel of FD with various moieties attached to the carbon cagewas developed using 
cyclopropanation reactions to determine the effect various group additions have on the ability to 
inhibit FcεRI stimulation. For MC, 35 diff erent FD developed to date were tested and 12 of 
these signifi cantly ( p < 0.05) inhibited degranulation and cytokine production by >10%. For 
PBB, 15 different FD were screened and three inhibited PBB degranulation >10%, while 11 
inhibited cytokine production >10% (Supplementary Figure S2). Two representative FD are 
shown in Tables 1 – 4 ; TGA was observed to be one of the most efficient inhibitors and 
significantly reduced both degranulation and cytokine production in MC and PBB. However, 
Inos significantly inhibited degranulation and cytokine production in PBB (Tables 3 and 4 ) but 
significantly inhibited only cytokine production in MC; degranulation was not affected in MC. 
IC50 values were calculated by setting the FD dose that resulted in maximum inhibition to 100% 
and then extrapolating the dose at which 50% inhibition was seen. The majority of the 35 
compounds tested to date had no significant effect on FcεRI mediator release. These data 
demonstrate selective inhibition of FcεRI mediator release from primary human MC/PBB using 
nano-engineered FD that depends on the moieties added to the carbon cage. 
Table 1 Degranulation (±SD) and GMCSF-cytokine production (±SD) in TGA treated and 
untreated mice. 
Mean percent degranulation (±SD) in TGA treated and untreated MC  
Mast cells 
no XL  XL  TGA+XL*†  %inh  IC50(μg/mL)  
Exp 1  3.4  76.7  39.1  48.9  
Exp 2  3.2  81.1  50.1  38.2  
Exp 3  5.5  74.5  53.4  28.3  
Exp 4  4  77.9  40.1  48.5  
Exp 5  8.1  78.5  52.7  32.8  
Average  4.8 (±2.0) 77.7(±2.4) 47.1(±6.9) 39.3(±9.2) 10.9(±3.5) 
* TGA Treatment @ 10 μg/mL. † p value = 0.0001. 
Mean percent GMCSF-cytokine production (±SD) in TGA treated and untreated MC 
Mast cells 
no XL  XL  TGA+XL*†  %inh IC50(μg/mL)   
Exp 1  50.4  211.4  69.5  67.8  
Exp 2  135.4  893.8  121.9  84.9  
Exp 3  91.6  309.5  104.5  66.2  
Exp 4  65.4  271.4  74.1  72.7  
Exp 5  105.4  741  43.4  95.2  
Average  89.6 (±33.4) 485.4(±309.8) 82.7(±30.8) 77.4(±12.4) 3.3(±0.6) 
* TGA Treatment @ 10 μg/mL. † p value = 0.02. 
 
Mechanisms of MC-FcεRI inhibition 
In order to understand how TGA and Inos diff erentially influence FcεRI-dependent mediator 
release, we first examined those events that occur immediately (within 30 minutes) upon FcεRI 
activation. The activation of MC and PBB FcεRI leading to degranulation is calcium dependent 
and induces elevated cellular levels of ROS.29,30 We hypothesized that the underlying mechanism 
of inhibition involved the blocking of FcεRI-mediated calcium and ROS responses based on 
previous studies with mixed isomer FDs.19 We compared the responses of MC treated with TGA 
or Inos. The increase in FcεRI-induced intracellular calcium stores release ( Figure 1A ) and 
ROS ( Figure 1B ) upon FcεRI cross-linking was inhibited with TGA. However, Inos 
preincubation did not affect calcium ( Figure 1C ) or ROS ( Figure 1D ) levels. Gene microarray 
data further suggests that TGA and Inos differentially influence FcεRI-associated signaling 
molecules involved in calcium stores release and oxidative stress (manuscript in preparation). 
Thus, TGA and Inos differentially affect ROS and calcium responses induced by FcεRI 
activation. 
Table 2 Degranulation (±SD) and GMCSF-cytokine production (±SD) in Inos treated and 
untreated mast cells. 
Mean percent degranulation (±SD) in Inos treated and untreated MC 
Mast cells 
no XL  XL  Inos+XL*†  %inh  IC50 (μg/mL)  
Exp 1  3.4  76.7  78.1  1.9  
Exp 2  3.2  81.1  80.3  1  
Exp 3  5.5  74.5  70.2  5.8  
Exp 4  4  77.9  75.5  3.1  
Exp 5  8.1  78.5  91.6  16.8  
Average  4.8(±2.0) 77.7(±2.4) 79.1 (±7.9)  3.3(±2.4)  
*Inos Treatment @ 10 μg/mL. † p value = 0.358. 
Mean percent GMCSF-cytokine production (±SD) in Inos treated and untreated MC 
Mast cells 
no XL  XL  Inos+XL*†  %inh  IC50 (μg/mL)  
Exp 1  50.4  211.4  11.9  94.4  
Exp 2  135.4  893.8  20.4  97.7  
Exp 3  91.6  309.5  23.5  92.4  
Exp 4  65.4  271.4  63.1  76.8  
Exp 5  105.4  741  43.4  95.2  
Average  89.6(±33.4) 485.4(±309.8) 32.5(±20.6) 91.3(±8.3) 1.9(±1.1) 
* Inos Treatment @ 10 μg/mL.† p value = 0.006. 
 
FD block early FcεRI-activated signaling molecules 
To further investigate the early signaling events in FcεRI-dependent mediator release that are 
affected by TGA or Inos, we performed Western blotting analysis using phospho-specifi c 
antibodies. The phosphorylation of signaling intermediates is an important early step in FcεRI-
induced mediator release. 31 As seen in Figure 2, several signaling intermediates that were 
phosphorylated by FcεRI activation were inhibited by preincubation with both FD including 
phosphorylation of extracellular signal regulated kinases ½ (ERK1/2), p38-mitogen-activated 
protein kinase (p38 MAPK), linker of activated T cells (LAT), Rho family GTPase (RAC) serine 
threonine protein kinase (AKT), phosphoinositide 3-kinase (PI3-K), and v-src sarcoma viral 
oncogene homolog (SRC). For example, FD inhibition of MC signaling was time dependent as 
preincubation with TGA inhibited AKT phosphorylation 10%, 36%, and 43% at 3, 5 and, 10 
minutes, while Inos inhibited AKT phosphorylation 18%, 48%, and 42% at 3, 5 and, 10 minutes. 
Both FD dramatically reduced LAT phosphorylation at later time points with 36%, 72%, and 
69% for TGA and 33%, 79%, and 70% for Inos at 3, 5 and, 10 minutes, respectively. PI3-kinase, 
a kinase strongly associated with calcium flux, was dramatically inhibited by both compounds 
with TGA reducing phosphorylation by 15%, 35%, and 50%, while Inos reduced 
phosphorylation by 8%, 40%, and 56% at 3, 5, and 10 minutes, respectively. There were also 
variations in the phosphorylation of other signaling intermediates examined at several time 
points. Little change was observed with a phospho-Lyn Ab to the negative regulatory tyrosine, a 
kinase with positive and negative signaling roles in MC. 32 Thus, molecules previously 
implicated in the release of calcium stores and ROS production in response to FcεRI aggregation 
were inhibited by certain FD. However, differences in how TGA and Inos inhibit FcεRI mediator 
release were not due to differential phosphorylation of the signaling molecules examined. 
Table 3 Degranulation (±SD) and IL-13 cytokine production (±SD) in TGA treated and 
untreated peripheral blood basophils. 
Mean percent degranulation (±SD) in TGA treated and untreated PBB 
Peripheral Blood Basophils 
 no XL  XL  TGA+XL*†  %inh  IC50 (μg/mL) 
Exp 1  7.3  35  31  11.4  
Exp 2  22.2  37  34  8.1  
Exp 3  16.8  36  24  33.3  
Exp 4  8.1  43  40  6.9  
Exp 5  9.5  21  17  19  
Exp 6  17.8  62.5  51  18.4  
Exp 7  9.2  64  63  1.56  
Exp 8  11  83  78  6  
Exp 9  19.2  27.5  17  38.1  
Average  13.5 (±5.5) 45.4(±20.1) 39.4(±7.0) 15.8(±4.2) 9.9(±2.9) 
* TGA Treatment @ 5 μg/mL.† p value = 0.001. 
Mean percent IL-13-cytokine production (±SD) in TGA treated and untreated PBB 
Peripheral Blood Basophils 
 no XL  XL  TGA+XL*†  %inh  IC50 (μg/mL) 
Exp 1  42.8  252  119.5  52.6  
Exp 2  12.6  297.5  35  88.2  
Exp 3  16.4  102.5  52.5  48.8  
Exp 4  39.4  137.5  110  20  
Average  27.8(±92.4) 197.4(±92.4) 79.3(±41.8) 52.4(±28.0) 10.6(±3.4) 
* TGA Treatment @ 5 μg/mL.† p value = 0.029. 
 
Gene microarray analysis of TGA and Inos-treated MC 
Given that optimal inhibition of MC or PBB secretion was observed after overnight 
preincubation with FD, we hypothesized that a transcriptional mechanism of action was 
involved. Microarray analysis was used to obtain a broad overview of those FcεRI-associated 
signaling molecules influenced by TGA and Inos preincubation following FcεRI activation at 
later (2 hours) times. Of the approximately 31,000 genes examined, the level of expression of 
1,771 increased at least 10% in MCs following cross-linking of FcεRI. In cells pretreated with 
TGA 2,603 of those were decreased at least 20% compared to non-TGA treated cells and 515 
demonstrated greater than 50% inhibition. Figure 3A represents several of those genes that were 
upregulated after 2 hours of FcεRI activation and significantly inhibited by TGA preincubation. 
The gene microarray data was verified at the protein level using Western blotting. For example, 
the gene for the tyrosine kinase Lyn was upregulated 293% upon FcεRI stimulation. However, 
gene expression levels were reduced by 51% at 2 hours that resulted in a 92% inhibition at the 
protein level observed at 6 hours ( Figure 3 ). E74-like factor 2 (ELF-2), which transcriptionally 
regulates Lyn, was also downregulated 47% suggesting Lyn is controlled at the 
transcription/translation level and protein level after two hours of FcεRI aggregation but not after 
10 minutes of activation. Conversely, Fyn, which was not inhibited at the genetic level (not 
shown) had no change in protein levels when preincubated with TGA ( Figure 3 -insert). Several 
other molecules, including ADAM10, MAP2K, BTK, and Syk, were inhibited at the gene level 
that resulted in lower protein levels. The ability to downregulate multiple components of a 
signaling pathway is novel and may provide a platform for engineering potent anti-inflammatory 
compounds. Our results indicate the ability to block both the activation as well as the expression 
of distinct signaling molecules within the FcεRI pathway. 
There was a dramatic diff erence in the FcεRI genes affected by Inos compared to TGA. In cells 
preincubated with this FD, only 741 genes were decreased at least 20% compared to non-FD 
treated cells and 92 demonstrated greater than 50% inhibition. Instead, there was a dramatic 
increase in expression of genes associated with inhibitory signaling. Th e Inos FD had 6 times 
more (1,847) genes upregulated compare to TGA (322) (Supplemental File 2). Unlike with TGA, 
Inos induced the upregulation of over 20 protein tyrosine phosphatases (PTP) and dual-specifi 
city phosphatases (DUSP). The upregulation of several of these inhibitory molecules is shown in 
Figure 4 . For example, DUSP1 was upregulated 126% at the gene level at 2 hours and 99% at 6 
hours at the protein level ( Figure 4 -insert). Therefore, the inhibition of cytokine production by 
Inos (opposed to TGA) was due in part to increasing protein expression of PTP. Since TGA and 
Inos may be differentially affecting two groups of enzymes (kinases vs. PTP), the FD may be 
recognizing a common regulatory mechanism or motif in the signaling molecule. 
Table 4 Degranulation (±SD) and IL-13 cytokine production (±SD) in Inos treated and untreated 
peripheral blood basophils. 
Mean percent degranulation (±SD) in Inos treated and untreated PBB 
Peripheral Blood Basophils 
 no XL  XL  Inos+XL*†  %inh  IC50(μg/mL) 
Exp 1  7.3  35  23  34.2  
Exp 2  16.8  36  21  41.6  
Exp 3  12.6  41  36  12.1  
Exp 4  10.4  19  11  42.1  
Exp 5  12.9  62.5  60  4  
Exp 6  12.5  86  68  20.9  
Exp 7  11.4  76  76  0  
Average  12 (±2.9) 50.8 (±24.5) 42.1(±25.7) 22.1(±17.5) 17.8(±3.2) 
* Inos Treatment @ 5 μg/mL. † p value = 0.007. 
Mean percent IL-13-cytokine production (±SD) in Inos treated and untreated PBB 
Peripheral Blood Basophils 
 no XL  XL  Inos+XL *†  %inh  IC50 (μg/mL) 
Exp 1  42.8  252  7  97.2  
Exp 2  16.4  102.5  5  95.1  
Exp 3  1.2  51.8  10.1  80.5  
Average  29.6 (±18.7) 177.3 (±105.7) 6.0 (±1.4)  90.9(±9.0) 2.6(±1.2) 
* Inos Treatment @ 5 μg/mL. † p value = 0.05. 
 
Effects of FD on MC FcεRI-induced anaphylaxis and toxicological assessment 
To explore the in vivo effects of FD on MC responses, we tested the degranulation and cytokine-
blocking TGA and the cytokine blocking Inos on MC-induced anaphylaxis. DNP-IgEsensitized 
animals injected i.p. with DNP-BSA demonstrated a characteristic drop in core body temperature 
resulting from MC-driven anaphylactic shock. When mice were injected with TGA before FcεRI 
challenge, there was a significant reduction in the anaphylactic-induced drop in core body 
temperature and behavioral responses that accompany anaphylactic shock ( Figure 5A ). 
However, Inos had no effect on MC-induced anaphylaxis ( Figure 5B ). As expected, serum 
histamine levels were significantly lower in animals treated with the degranulation and cytokine 
inhibitor compared to controls ( Figure 5C ). There was no significant increase in serum activity 
of ALT and AST between the untreated and fullerene-treated mice injected with FD 
concentrations 50-fold higher than that needed for in vivo efficacy ( Table 5 ; tail vein or i.p. 
routes gave the same result). The injections were well tolerated and no change in behavior or 
body weights was noted. These experiments demonstrate that the efficacy of FD in vivo depends 
on how the carbon cage is derivatized and suggest they can be engineered at the nano-scale level 
to perform specific cellular functions. 
Discussion 
This study examines how FD impact MC and PBB responses following FcεRI challenge. The 
impetus for these studies was based on the observation that fullerenes are potent ROS 
scavengers, and there is evidence that ROS is involved in FcεRI signaling. 
In addition, we had shown previously that water-soluble FD could affect MC/PBB responses, 
although the compounds used in those studies are not viable therapeutic candidates. Thus, next 
generation FD were developed and investigated to determine which side chains most affected 
FcεRI signaling pathways. Several new FD were identified that inhibited MC/PBB FcεRI 
responses and two were selected for further in vitro and in vivo studies. Several observations 
were noted. First, there were striking differences in the biological activity of FD that was 
dependent on the side chain moieties added to the carbon cage. Second, the differences in FD 
structures revealed selectivity in FcεRI pathway inhibition between MC and PBB; Inos inhibited 
cytokine production only in MC but inhibited both degranulation and the cytokine release in 
PBB. Third, it is shown for the first time that FD affect both phosphorylation of signaling 
molecules as well as gene expression. Fourth, while previous studies suggest FD induce 
oxidative stress 33–36 and apoptosis, 35,37 our studies contradict these findings and suggest FD 
block oxidative stress and apoptosisrelated genes that were upregulated by FcεRI cross-linking. 
Lastly, this study expands the wide range of biological pathways that FD affect and may 
represent a new way to control MC responses before they occur. 
 
Figure 1. Fullerene derivatives inhibit anti-FcεRI-dependent increases in intracellular calcium and 
ROS levels. Cells were incubated with or without FD (10 μg/mL) overnight. The next day cells were 
challenged with anti-FcεRI (3B4; 1 μg/mL) and calcium stores release was determined by the 340/380 nm 
ratio (A and B) and ROS measured by DCF detection at 523 nm (C and D). A and C contain cells 
incubated with the TGA FD and B and D contain cells incubated with the Inos FD (10 μg/mL). The dark 
gray squares are the unchallenged negative control, dark thick solid black line is the anti-FcεRI 
challenged positive control cells, and the two light gray lines (hashed and double line) are the anti-FcεRI 
challenged cells pretreated with respective FD. Results are representative of at least three separate 
experiments. 
Complete inhibition of FcεRI MC/PBB mediator release was not observed with TGA, yet it was 
sufficient to improve disease outcomes. This result is consistent with those reported on MC-
blunting pharmaceuticals currently prescribed to patients. Cromolyn, an MC-stabilizer and 
current treatment for asthmatic patients (Nasalcrom, Intal, Opticrom), has been shown to inhibit 
MC activation in vitro in the same range that FD inhibit MC mediator release (35%–80% 
inhibition). 38–42 Cromolyn was first discovered as an MC stabilizer (such as FD) and is 
currently prescribed by physicians to prevent diseases associated with MC activation. Similarly, 
the anti-IgE therapy Xolair (which indirectly blocks MC degranulation by depleting IgE levels) 
does not completely inhibit FcεRI mediator release. 43–46 Therefore, MC targeting and 
complete inhibition of FcεRI mediator release in vitro is not necessary for in vivo efficacy.  
Our results are consistent with studies demonstrating a lack of toxicity of FD using in vitro cell 
culture assays.18 No toxicity was observed using up to 100 μg/mL, well above concentrations in 
which efficacy was observed in vitro and in vivo . In contrast to most studies conducted 
previously on FD toxicity, our current study employed thoroughly purified and characterized FD, 
limiting the likelihood of confounding results due to sample impurities. In separate experiments, 
the in vivo administration (i.v. daily; 200 ng/3 weeks) of TGA to mice showed no notable 
differences in behavior, and there were no abnormalities observed upon gross pathological 
examination. No mutagenic potential (using the Ames test) was observed (not shown). No 
adverse reactions were observed in the anaphylaxis model, when FD were injected and no liver 
damage was noted at the concentrations sufficient for in vivo efficacy. A full toxicity profile is 
currently being performed for each candidate based on their MC/PBB inhibitory capabilities. 
Taken together, the derivatives described herein are not cytotoxic to several cell lines tested and 
appear to have no acute in vivo cytotoxic effects. 
 
Figure 2. FcεRI-mediated activation of early signaling molecules is inhibited by FD. MC were 
pretreated with Inos or TGA (10 μg/mL) overnight at 37°C/6% CO 2. The next day washed cells were 
activated with or without anti-FcεRI (1 μg/mL) for the indicated times and lysed using protocols 
described above. Two separate 10% Tris-Glycine gels were used for sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting performed with the indicated 
phosphorylation-specific (i.e., phosph-Lyn) antibodies . To ensure equal loading, an antiactin antibody 
was used in parallel. The intensity of each band was detected and quantified using an Odyssey imaging 
system. Band intensities are presented as a ratio compared to antiactin band intensities probed in the same 
lane and presented for each time point in the colored graphs on the right side. Results are representative of 
three separate experiments. The two gels were run side-by-side, so that each time point could be 
examined, and are shown next to each other. 
Empty cage fullerenes—without appropriate side chain moieties—are generally not biologically 
suitable for therapeutic development. In order to harness the biological potential of the core 
carbon fullerene cage, chemical structures are added directly to the cage to make them 
compatible with biological systems. A similar strategy has previously been employed to target 
the antioxidant properties of FD for neuronal protection.9 We used a similar strategy to add 
distinct side chain moieties with various chemical properties that were hypothesized to interfere 
with FcεRI mediator release. We chose to focus on the use of carbon cages with C70 structures, 
instead of C60 , as bis additions to C70 occurs exclusively on each pole of the oblate spheroid 
cage. Th is strategy offers enhanced control over the topography of the addition groups thus 
reducing the potential number of isomers, a key issue in the FDA approval process. We have also 
observed that the C70 is a more efficient scavenger of ROS compared to C60 (submitted for 
publication, Bioconjugate Chemistry ), which is understandable given the increased number of C 
= C bonds in the C70 cage. 
The sugar inositol is involved in several biological pathways in inflammation including FcεRI 
signaling. 47 Interestingly, unlike TGA, Inos does not interfere with degranulation in MC but is 
highly effective at blocking cytokine production in MC, while it does inhibit degranulation in 
PBB. This suggests that the Inos interacts and/or indirectly inhibits a signaling molecule found in 
human MC FcεRI signaling and not in PBB. Mechanistically, the variations in how Inos and 
TGA diff erentially inhibit intercellular FcεRI responses between MC and PBB may be 
explained in how they affect Lyn. In mouse Lyn -/- basophils, FcεRI-mediated degranulation is 
inhibited.48 However, Lyn -/- BMMCs can have the opposite phenotype with degranulation being 
upregulated49 or inhibited depending on the Lyn/Fyn ratio.50 In rat basophil leukaemia (RBL) 
cells, degranulation can be inhibited, while TNF-α secretion is unaffected by overexpressing 
Lyn .51 There is also precedence demonstrating that intracellular FcεRI-signaling pathways 
diverge subsequent to activation in MC and PBB. It is well known that concentrations of FcεRI 
cross-linking agents leading to optimal cytokine production are consistently lower than 
concentrations needed for optimal degranulation.52 The release of preformed mediators through 
FcεRI-mediated degranulation follows the activation of protein kinase C (PKC) and calcium 
mobilization; cytokine and chemokine production requires activation of mitogen-activated 
protein kinases p38 and c-Jun N-terminal kinases (JNK), whereas lipid mediator production 
follows the activation of ERK1/2 pathway .53 A central control point that possibly mediates 
FcεRI-signals leading to cytokine production and mediator release occurs at LAT;54 the 
phosphoactivation of this signaling molecule was affected significantly (see below). In mice, 
tumor necrosis factor-associated factor 6 (TRAF6) is specifically required for cytokine 
generating FcεRI signals of NF-κB, p38 MAP kinase, and JNK yet is not required for proximal 
signaling and subsequent degranulation.55 Our plan is to identify what signaling molecule(s) bind 
to TGA and Inos using cell lysates from differentially activated MC and PBB. 
 
Figure 3. Microarray analysis of FcεRI activated genes affected by TGA. MC were pretreated with or 
without 10 μg/mL TGA overnight at 37°C/6% CO 2 . The next daycells were washed and challenged with 
(+) or without (−) anti-FcεRI (1 μg/mL) for 2 hours. Cell pellets were used for RNA isolation and gene 
microarray as described above or used for Western blotting. Each condition was performed in triplicate. 
What is shown is the mean of the relative intensities of each gene (±SD of six observed values). The red 
bar/numbers is the percent increase in resting cells compared to FcεRI-activated cells and the black 
bar/numbers is the percent inhibition comparing FD pretreated and activated cells compared to non-FD-
treated FcεRI-treated cells. For Western blotting, approximately 200,000 cell equivalents/lane were 
loaded onto a 10% tris-glycine gel and Western blotted with the indicated Abs as described previously.20 
To begin to explore at what point the FD affect early FcεRI-signaling pathways postactivation 
and why certain FD differentially affected mediator release, we performed Western blotting with 
several phospho-specifi c antibodies for FcεRI associated signaling molecules. It is shown for the 
first time that FD can inhibit the phosphorylation of signaling intermediates involved with 
calcium and ROS generation. The Inos and TGA both reduced the phosphorylation of several 
intermediates, especially LAT and PI3-K. Our results are consistent with other findings showing 
that LAT is critical for calcium mobilization53 and MC from LAT-defi cient mice have inhibited 
FcεRI-mediated degranulation. Similarly, PI3-K is critical for functional responses in MC as the 
PI3-K inhibitors wortmannin and LY294002 inhibit antigen-induced calcium mobilization, 
degranulation and cytokine production by murine and human MC.31 However, the activation of 
these signaling molecules is dependent on prior activation of Lyn. In our current study, the early 
(10 minutes) phosphorylation of Lyn was not infl uenced by either FD. 
 
Figure 4. Microarray analysis of FcεRI activated genes affected by Inos. MC were treated and 
analyzed as in Figure 3. Given the large size of CD45 (220 kDa) and difficulty in gel-to-membrane 
transfer FACS analysis was used to monitor upregulation: mouse IgG Isotype control (black line), 
untreated FITC labeled CD45 (gray filled), and Inos treated Fluorescein isothiocyanate (FITC) labeled 
CD45 (red filled). 
To better understand the differences in Inos and TGA effects on MC FcεRI-signaling, gene 
microarray experiments were used. These studies revealed that TGA profoundly reduced the 
FcεRI-induced activation of over 1,000 genes that was selectively verified at the protein level. 
Several important discoveries were made from these experiments. First, many upregulated genes 
were identified that were previously not associated with MC/PBB FcεRI signaling. These include 
tank-binding kinase 1 (TBK-1) involved in mediating NFκB activation, 56 Poly (ADP-ribose) 
polymerase 1 (PARP1) previously shown to be a target for the development of new therapeutic 
strategies in the treatment of lung disorders such as asthma,57 calumenin (CALU) that is a 
calcium-binding protein localized in the endoplasmic reticulum (ER) involved in protein folding 
and sorting, a disintegrin and metalloproteinase (ADAM10), SOX9, tumor necrosis factor alpha-
induced protein 1 (TNFAIP1) an immediate-early response gene of endothelium induced by 
TNF-α, 58 and SAMD9 involved in the regulation of TNF-α signaling.59,60 Second, these are 
the first data to demonstrate that FD can influence gene expression. Given that current dogma 
suggest their biological activity depends solely on their antioxidant properties, these results 
suggest FD effects are not entirely due to ROS scavenging capabilities. Third, it proves that 
fullerenes as a class cannot be considered to behave the same in vitro, in situ , and in vivo. Two 
C70 -based derivatives with very similar molecular weights had practically no common effects in 
the microarray studies. This further reiterates the key message from these studies that the 
biological effects of FD critically depend on the side chains added to the core carbon cage. 
TGA inhibits MC FcεRI-mediated activation in vivo as shown in the anaphylaxis model used in 
Figure 5 . Interestingly, Inos, the FD that have no effect on MC FcεRI degranulation but are a 
potent cytokine inhibitor, did not significantly inhibit anaphylaxis using the same model ( Figure 
5B ) suggesting FD are inhibiting preformed MC mediators. We provide initial mechanistic 
evidence for the ability of FD to suppress MC and PBB secretion by affecting transcription of a 
select group of FcεRI-signaling molecules. While the FD are likely to be influencing other cell 
types, our goal herein was to first identify MC inhibitors and then begin to explore their effects 
on other cell types. To this end, preliminary experiments using TGA suggest it may interfere 
with human B cell IgE production (not shown). 
 
Figure 5. FD blunt MC-driven anaphylaxis in vivo . Mice (5 per group) were sensitized with 50 μg 
DNP-IgE in 100 μl PBS. Two hours later the mice were injected i.p. with PBS alone or 100 ng of FD that 
inhibit degranulation and cytokine production 
(A) or cytokine production only (B) in 100 μL PBS. The following day rectal temperatures were recorded 
before mice were challenged i.p. with 100 μg of DNP-BSA in 100 μL PBS. Temperatures were recorded 
every 10 minutes (up to 50 minutes) following challenge with DNP-BSA. (C) Increases in antigen-
induced serum histamine release is blunted by FD. Blood was collected from control (black bars), 
degranulation inhibiting FD (light gray bars) or cytokine inhibiting FD (dark gray bars) at 50 minutes and 
histamine content determined by ELISA. 
Table 5. No liver toxicity is detected following FD injection 
Day 2 Day 14 
 Inositol 
Treated 
TGA 
Treated 
Untreated Inositol 
Treated 
TGA 
Treated 
Untreated 
 n  Activity  n  Activity  n  Activity  n  Activity  n  Activity  n  Activity 
Aspartate 
aminotransferase 
(AST) 
3  27.6 
(±2.1)  
3  8.5 
(±2.3)  
3  29.5 
(±9.2)  
3  33.5 
(±4.2)  
3  29.8 
(±9.9)  
3  51.1 
(±4.1) 
Alanine 
aminotransferase 
(ALT) 
3  26.4 
(±2.0)  
3  29.2 
(±2.5)  
3  64.3 
(±11.5)  
3  44.2 
(±1.5)  
3  36.7 
(±6.6)  
3  47.0 
(±2.9) 
n = Number of Mice evaulated in Duplicates.  
Untreated = Normal Mice with PBS injection.  
Treated = Tail Vein injection of 100 μl of C70-inositol or C70-tetragylcolate. 
 
Conclusion 
These studies describe a platform for engineering MC/PBB inhibitors at the nano-scale based on 
FD and establish proof-of-principle for their use as a new way to treat MC/PBB-infl uenced 
diseases. Currently, MC/PBB-targeting FD are being developed that will be able to selectively 
deliver FD that inhibit activation responses alone or in combination with other therapeutics. 
Future studies are also aimed at developing next generation FD that are even more potent 
inhibitors of MC/PBB mediator release and investigating their use as new therapeutics for 
patients. 
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Supplementary Figure S2: Fullerene derivatives reduce degranulation and cytokine production 
from MC after anti-FcεRI activation. Cells were cultured with fixed concentrations of FD (10 μ
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minutes (A and B) or 24 hours (C and D) with optimal concentrations of αanti-FcεRI Abs (3B4; 
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demonstrated a significant ( p < 0.05) inhibition of at least >10% inhibition compared to 
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